Methods of treating 4-repeat tauopathies

a tauopathy and repeating technology, applied in the field of repeating tauopathy, can solve the problems of not being able to effectively treat any 4r tauopathy, pharmacological approaches and especially those aimed at disrupting tau pathology do not work, and the approach to disrupting tau pathology will not work

Active Publication Date: 2022-04-28
WOOLSEY PHARM INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no effective therapy for any 4R tauopathy.
In fact, every agent tested in the clinic thus far has failed to show an effect and most of these approaches involved directly antagonizing the pathologic effects of tau.
Thus, there is a wealth of evidence that pharmacological approaches and especially those aimed at disrupting tau pathology do not work and there is no expectation that any approach to disrupting tau pathology will work.
Without a complete understanding of the effects of these different mixtures and how they might relate to human metabolism (in males and females), there is no rational way to extrapolate from animal models to humans.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating 4-repeat tauopathies
  • Methods of treating 4-repeat tauopathies
  • Methods of treating 4-repeat tauopathies

Examples

Experimental program
Comparison scheme
Effect test

examples

[0092]Ten subjects 50-85 years old, meeting the National Institute of Neurological Disorders and Stroke-Society for Progressive Supranuclear Palsy (NINDS-SPSP) probable or possible PSP criteria, (Litvan 1996) as modified from the AL-108-231 trial (Boxer 2014) are enrolled. MRI at screening is consistent with PSP (≤4 microhemorrhages and no large strokes or severe white matter disease). They have Mini-Mental State Examination (MMSE) score 14-30 and have stable medications for 2 months prior to screening, including FDA approved Alzheimer's disease (AD) medications and Parkinson's disease medications. Subjects are excluded if they meet the National Institute on Aging-Alzheimer's Association Workgroups criteria for probable AD (McKhann 2011), if they have any medical condition other than PSP that could account for cognitive deficits (e.g., active seizure disorder, stroke, vascular dementia) or if they have a prominent and sustained response to levodopa therapy (suggestive of Parkinson's...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
w/waaaaaaaaaa
blood pressureaaaaaaaaaa
blood pressureaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the treatment patient with a 4-repeat (4R) tauopathy using a therapeutically effect amount of a rho kinase inhibitor. One preferred inhibitor is fasudil and preferred methods involve the daily oral administration of between 20 and 250 mg of fasudil. Preferred 4R tauopathies treatable according to the invention include progressive supranuclear palsy with Richardson syndrome (PSP-RS) and corticobasal syndrome with probable sporadic corticobasal degeneration.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional application 63 / 104,121, filed Oct. 22, 2020, the disclosure of which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]Proteinopathies are a group of conditions resulting from the improper folding or unfolding of a protein. They typically manifest as neurodegenerative disorders and are characterized by abnormal protein deposits or aggregates thought to result from conformational abnormalities that disrupt the normal placement of hydrophobic regions of the molecule into hydrophilic environments, causing the proteins to become insoluble and / or aggregate. In some cases, such as in prion diseases, the abnormal structures are thought to form nuclei for further protein deposition, initiating a kind of chain reaction of protein aggregation. The culprit proteins often are normal proteins with aggregates being formed after some post-translational modification, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/551
CPCA61K31/551
Inventor MACALLISTER, THOMASJACOBSON, SVEN
Owner WOOLSEY PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products